Indore pharma unit under fire as inspection flags 216 lapses
Written By : Ruchika Sharma
Published On 2025-10-13 08:09 GMT | Update On 2025-10-13 08:09 GMT
inspection
Advertisement
Indore: The heartbreaking deaths linked to contaminated Coldrif cough syrup have uncovered serious cracks in pharmaceutical manufacturing standards, leading to a major regulatory crackdown. A pharmaceutical unit in Indore has now been ordered to temporarily stop production after more than 200 deficiencies were found against established standards.
The joint inspection, conducted by the central and state government departments, took place in late September at the pharmaceutical unit operated by a private company in the Sanwer Road Industrial Area, said Chief Medical and Health Officer (CMHO) Dr Madhav Prasad Hasani.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.